2/6
08:11 am
teva
Is Teva Pharmaceutical Industries Limited (TEVA) an Undervalued Stock Relative to Its Long-Term Potential? [Yahoo! Finance]
Low
Report
Is Teva Pharmaceutical Industries Limited (TEVA) an Undervalued Stock Relative to Its Long-Term Potential? [Yahoo! Finance]
2/4
09:28 am
teva
Barclays Raises Teva Pharmaceutical (TEVA) PT to $38 Following Strong Q4 Earnings Beat [Yahoo! Finance]
Medium
Report
Barclays Raises Teva Pharmaceutical (TEVA) PT to $38 Following Strong Q4 Earnings Beat [Yahoo! Finance]
2/3
09:42 pm
teva
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory [Yahoo! Finance]
Medium
Report
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory [Yahoo! Finance]
1/31
07:03 pm
teva
Jim Cramer Highlights Teva Pharmaceutical's Growth Under CEO Richard Francis [Yahoo! Finance]
Medium
Report
Jim Cramer Highlights Teva Pharmaceutical's Growth Under CEO Richard Francis [Yahoo! Finance]
1/31
09:57 am
teva
Analysts See Pipeline Catalysts Driving Teva Pharmaceutical Industries Limited (TEVA)'s 2026 Growth Despite Revenue Headwinds [Yahoo! Finance]
Medium
Report
Analysts See Pipeline Catalysts Driving Teva Pharmaceutical Industries Limited (TEVA)'s 2026 Growth Despite Revenue Headwinds [Yahoo! Finance]
1/31
01:33 am
teva
Teva Pharmaceutical Industries (NYSE:TEVA) was upgraded by analysts at
W
Medium
Report
Teva Pharmaceutical Industries (NYSE:TEVA) was upgraded by analysts at
W
1/30
07:12 pm
teva
Does Teva's Return To Profitability And Branded-Drug Shift Reshape The Bull Case For TEVA? [Yahoo! Finance]
Medium
Report
Does Teva's Return To Profitability And Branded-Drug Shift Reshape The Bull Case For TEVA? [Yahoo! Finance]
1/30
11:38 am
teva
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at Barclays PLC from $35.00 to $38.00. They now have an "overweight" rating on the stock.
Low
Report
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at Barclays PLC from $35.00 to $38.00. They now have an "overweight" rating on the stock.
1/29
10:35 am
teva
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at Truist Financial Corporation from $36.00 to $38.00. They now have a "buy" rating on the stock.
Low
Report
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at Truist Financial Corporation from $36.00 to $38.00. They now have a "buy" rating on the stock.
1/29
10:35 am
teva
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at Scotiabank from $35.00 to $40.00. They now have a "sector outperform" rating on the stock.
Low
Report
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at Scotiabank from $35.00 to $40.00. They now have a "sector outperform" rating on the stock.
1/29
12:23 am
teva
Teva Pharmaceutical Industries Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Teva Pharmaceutical Industries Q4 Earnings Call Highlights [Yahoo! Finance]
1/28
08:27 am
teva
Medincell - UZEDY®: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%) [Yahoo! Finance]
Medium
Report
Medincell - UZEDY®: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%) [Yahoo! Finance]
1/28
07:38 am
teva
Earnings Snapshot: Teva Pharmaceutical Industries tops Q4 estimates; initiates FY26 outlook below forecast [Seeking Alpha]
Medium
Report
Earnings Snapshot: Teva Pharmaceutical Industries tops Q4 estimates; initiates FY26 outlook below forecast [Seeking Alpha]
1/28
07:00 am
teva
Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
Low
Report
Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
1/28
05:13 am
teva
Pharma Data Integrity Auditor Masterclass Training Course: Department-Level Audit Strategies, Critical Findings, and Regulatory Expectations (Online Event: Apr 22nd - Apr 23rd, 2026) [Yahoo! Finance]
Low
Report
Pharma Data Integrity Auditor Masterclass Training Course: Department-Level Audit Strategies, Critical Findings, and Regulatory Expectations (Online Event: Apr 22nd - Apr 23rd, 2026) [Yahoo! Finance]
1/27
08:00 am
teva
Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’
Low
Report
Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’
1/26
02:17 am
teva
Samsung Epis Holdings Reports Fourth Quarter and Fiscal Year 2025 Financial Results [Yahoo! Finance]
Low
Report
Samsung Epis Holdings Reports Fourth Quarter and Fiscal Year 2025 Financial Results [Yahoo! Finance]
1/24
09:07 am
teva
Is There An Opportunity With Teva Pharmaceutical Industries Limited's (NYSE:TEVA) 45% Undervaluation? [Yahoo! Finance]
Low
Report
Is There An Opportunity With Teva Pharmaceutical Industries Limited's (NYSE:TEVA) 45% Undervaluation? [Yahoo! Finance]
1/20
01:27 pm
teva
Medincell: Half-year Liquidity Contract Statement [Yahoo! Finance]
Low
Report
Medincell: Half-year Liquidity Contract Statement [Yahoo! Finance]
1/18
01:00 am
teva
1/14
05:02 pm
teva
AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine
Low
Report
AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine
1/13
07:46 pm
teva
Is It Too Late To Reassess Teva (TEVA) After A 55% One Year Rally? [Yahoo! Finance]
Low
Report
Is It Too Late To Reassess Teva (TEVA) After A 55% One Year Rally? [Yahoo! Finance]
1/13
07:07 pm
teva
Public advisory -Teva Octreotide for injectable suspension recalled due to potential drug quality issues [Yahoo! Finance]
Low
Report
Public advisory -Teva Octreotide for injectable suspension recalled due to potential drug quality issues [Yahoo! Finance]
1/11
07:40 pm
teva
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation [Yahoo! Finance]
Low
Report
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation [Yahoo! Finance]
1/11
06:00 pm
teva
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation
Low
Report
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation